Cargando…

Icotinib versus docetaxel used in lung adenocarcinoma patients who failed platinum-based chemotherapy: a retrospective study

BACKGROUND: The efficacy and safety of epidermal growth factor receptor tyrosine kinase inhibitors have been studied worldwide. However, there are few reports directly comparing the efficacy and safety between icotinib and docetaxel as second-line treatment in lung adenocarcinoma patients who have f...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Wei, Zhang, Yan, Xiong, Yu, Dai, Feng-juan, Fan, Qing-xia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4936811/
https://www.ncbi.nlm.nih.gov/pubmed/27445494
http://dx.doi.org/10.2147/OTT.S99434
_version_ 1782441616942825472
author He, Wei
Zhang, Yan
Xiong, Yu
Dai, Feng-juan
Fan, Qing-xia
author_facet He, Wei
Zhang, Yan
Xiong, Yu
Dai, Feng-juan
Fan, Qing-xia
author_sort He, Wei
collection PubMed
description BACKGROUND: The efficacy and safety of epidermal growth factor receptor tyrosine kinase inhibitors have been studied worldwide. However, there are few reports directly comparing the efficacy and safety between icotinib and docetaxel as second-line treatment in lung adenocarcinoma patients who have failed platinum-based chemotherapy. This article offers insight into this field. METHODS: A total of 137 patients with stage III or IV lung adenocarcinoma who had progressed on first-line platinum-based therapies and received icotinib or docetaxel therapy between October 2011 and February 2013 were retrospectively reviewed. Patients in the icotinib group received oral icotinib at a dose of 125 mg tid, while patients in the docetaxel group received infusion docetaxel at a dose of 75 mg/m(2) on day 1 of every 21 days (four to six cycles) until disease progression or unacceptable toxicity occurred after which best supportive care was given. RESULTS: There was no statistically significant difference in the objective response rate (23.3% vs 12.5%, P=0.103), progression-free survival (121 days vs 106 days, P=0.083), and overall survival (307 days vs 254 days, P=0.070) between the two groups. As compared to the docetaxel group, the disease control rate (75.3% vs 54.7%, P=0.011) was significantly better in the icotinib group. In the icotinib group, the most common adverse events were rash (35.62%) and diarrhea (24.66%), whereas in the docetaxel group, elevation of transaminase (37.50%), leukopenia (50.00%), and anemia (54.69%) were the most common. CONCLUSION: Icotinib had similar efficacy and a lower adverse events rate in epidermal growth factor receptor-unselected patients as compared to docetaxel, thereby making it an effective second-line therapy option for lung adenocarcinoma.
format Online
Article
Text
id pubmed-4936811
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-49368112016-07-21 Icotinib versus docetaxel used in lung adenocarcinoma patients who failed platinum-based chemotherapy: a retrospective study He, Wei Zhang, Yan Xiong, Yu Dai, Feng-juan Fan, Qing-xia Onco Targets Ther Original Research BACKGROUND: The efficacy and safety of epidermal growth factor receptor tyrosine kinase inhibitors have been studied worldwide. However, there are few reports directly comparing the efficacy and safety between icotinib and docetaxel as second-line treatment in lung adenocarcinoma patients who have failed platinum-based chemotherapy. This article offers insight into this field. METHODS: A total of 137 patients with stage III or IV lung adenocarcinoma who had progressed on first-line platinum-based therapies and received icotinib or docetaxel therapy between October 2011 and February 2013 were retrospectively reviewed. Patients in the icotinib group received oral icotinib at a dose of 125 mg tid, while patients in the docetaxel group received infusion docetaxel at a dose of 75 mg/m(2) on day 1 of every 21 days (four to six cycles) until disease progression or unacceptable toxicity occurred after which best supportive care was given. RESULTS: There was no statistically significant difference in the objective response rate (23.3% vs 12.5%, P=0.103), progression-free survival (121 days vs 106 days, P=0.083), and overall survival (307 days vs 254 days, P=0.070) between the two groups. As compared to the docetaxel group, the disease control rate (75.3% vs 54.7%, P=0.011) was significantly better in the icotinib group. In the icotinib group, the most common adverse events were rash (35.62%) and diarrhea (24.66%), whereas in the docetaxel group, elevation of transaminase (37.50%), leukopenia (50.00%), and anemia (54.69%) were the most common. CONCLUSION: Icotinib had similar efficacy and a lower adverse events rate in epidermal growth factor receptor-unselected patients as compared to docetaxel, thereby making it an effective second-line therapy option for lung adenocarcinoma. Dove Medical Press 2016-07-01 /pmc/articles/PMC4936811/ /pubmed/27445494 http://dx.doi.org/10.2147/OTT.S99434 Text en © 2016 He et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
He, Wei
Zhang, Yan
Xiong, Yu
Dai, Feng-juan
Fan, Qing-xia
Icotinib versus docetaxel used in lung adenocarcinoma patients who failed platinum-based chemotherapy: a retrospective study
title Icotinib versus docetaxel used in lung adenocarcinoma patients who failed platinum-based chemotherapy: a retrospective study
title_full Icotinib versus docetaxel used in lung adenocarcinoma patients who failed platinum-based chemotherapy: a retrospective study
title_fullStr Icotinib versus docetaxel used in lung adenocarcinoma patients who failed platinum-based chemotherapy: a retrospective study
title_full_unstemmed Icotinib versus docetaxel used in lung adenocarcinoma patients who failed platinum-based chemotherapy: a retrospective study
title_short Icotinib versus docetaxel used in lung adenocarcinoma patients who failed platinum-based chemotherapy: a retrospective study
title_sort icotinib versus docetaxel used in lung adenocarcinoma patients who failed platinum-based chemotherapy: a retrospective study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4936811/
https://www.ncbi.nlm.nih.gov/pubmed/27445494
http://dx.doi.org/10.2147/OTT.S99434
work_keys_str_mv AT hewei icotinibversusdocetaxelusedinlungadenocarcinomapatientswhofailedplatinumbasedchemotherapyaretrospectivestudy
AT zhangyan icotinibversusdocetaxelusedinlungadenocarcinomapatientswhofailedplatinumbasedchemotherapyaretrospectivestudy
AT xiongyu icotinibversusdocetaxelusedinlungadenocarcinomapatientswhofailedplatinumbasedchemotherapyaretrospectivestudy
AT daifengjuan icotinibversusdocetaxelusedinlungadenocarcinomapatientswhofailedplatinumbasedchemotherapyaretrospectivestudy
AT fanqingxia icotinibversusdocetaxelusedinlungadenocarcinomapatientswhofailedplatinumbasedchemotherapyaretrospectivestudy